knowledge -WSS

knowledge

author：comprehensive 2025-09-27 12:58:23 - browse：6987

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： H5N1 bird flu virus started spreading in cows in Texas in December

WSS

MultiPlan and major insurers sued for alleged medical price

Why hospitals are withdrawing from US News rankings

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Sanofi seeks simpler, safer CRISPR sickle cell cure

Sanofi seeks simpler, safer CRISPR sickle cell cure

entertainment

knowledge

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Getting Alzheimer's drug Leqembi to patients can be a challenge

FDA approval of Sarepta Duchenne genetic therapy gives me hope

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Trump demands the U.S. pay no more for drugs than other countries … again

Google and Epic fight stronger regulation of AI in health care

Walensky prepares to leave CDC — and Congress — behind

H5N1 bird flu found in pasteurized milk: what we know

Bright Health sells Medicare Advantage business to Molina

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

focus

Element Biosciences CEO lays out genome sequencing strategy

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Health care needs a new profession: neuroimaging counseling

Why hospitals are withdrawing from US News rankings

FTC falls short on scrutinizing hospital mergers, study says

Google and Epic fight stronger regulation of AI in health care

leisure time

explore

hotspot

hotspot